Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chong-Jen Yu

Showing results (311-320 of 478) with videos related to

Pageof 48
Sort By:
Journal of Cancer|August 19, 2017
Outcomes of cancer therapy administered to treatment-naïve lung cancer patients in the intensive care unitYen-Fu Chen, Jou-Wei Lin, Chao-Chi Ho, et al.
Journal of Magnetic Resonance Imaging : JMRI|April 21, 2012
Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatinYeun-Chung Chang, Chong-Jen Yu, Chung-Ming Chen, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 10, 2015
COPD in Taiwan: a National Epidemiology SurveyShih-Lung Cheng, Ming-Cheng Chan, Chin-Chou Wang, et al.
Frontiers in Oncology|January 25, 2021
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry CohortSheng-Kai Liang, Li-Ta Keng, Chia-Hao Chang, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|April 12, 2025
The therapeutic impact of maximum chemotherapy possession days during three consecutive months in non-tuberculous mycobacterial lung disease: A real-world experiencePing-Huai Wang, Yu-Feng Wei, Chia-Jung Liu, et al.
Future Microbiology|December 13, 2016
Evaluation of the automated Becton Dickinson MAX real-time PCR platform for detection of Pneumocystis jiroveciiJung-Yien Chien, Chia-Jung Liu, Pei-Chien Chuang, et al.
Journal of Fungi (Basel, Switzerland)|July 2, 2021
Establishing Aspergillus-Specific IgG Cut-Off Level for Chronic Pulmonary Aspergillosis Diagnosis: Multicenter Prospective Cohort StudyMeng-Rui Lee, Hung-Ling Huang, Li-Ta Keng, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|September 25, 2018
Impact of prior pulmonary tuberculosis in treatment outcomes of HCAP and CAP patients in intensive care unitsFan-Min Lin, Jia-Yih Feng, Wen-Feng Fang, et al.
Infectious Diseases and Therapy|February 11, 2023
Incidence of and Risk Factors for Acute Kidney Injury During Antituberculosis Treatment: A Prospective Cohort Study and Literature ReviewChia-Hao Chang, Lih-Yu Chang, Jen-Chung Ko, et al.
BMC Cancer|March 14, 2023
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitorsChun-Ta Huang, Chih-An Lin, Te-Jen Su, et al.
Pageof 48

Showing results (311-320 of 478) with videos related to

Sort By:
Pageof 48
Journal of Cancer|August 19, 2017
Outcomes of cancer therapy administered to treatment-naïve lung cancer patients in the intensive care unitYen-Fu Chen, Jou-Wei Lin, Chao-Chi Ho, et al.
Journal of Magnetic Resonance Imaging : JMRI|April 21, 2012
Dynamic contrast-enhanced MRI in advanced nonsmall-cell lung cancer patients treated with first-line bevacizumab, gemcitabine, and cisplatinYeun-Chung Chang, Chong-Jen Yu, Chung-Ming Chen, et al.
International Journal of Chronic Obstructive Pulmonary Disease|December 10, 2015
COPD in Taiwan: a National Epidemiology SurveyShih-Lung Cheng, Ming-Cheng Chan, Chin-Chou Wang, et al.
Frontiers in Oncology|January 25, 2021
Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry CohortSheng-Kai Liang, Li-Ta Keng, Chia-Hao Chang, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|April 12, 2025
The therapeutic impact of maximum chemotherapy possession days during three consecutive months in non-tuberculous mycobacterial lung disease: A real-world experiencePing-Huai Wang, Yu-Feng Wei, Chia-Jung Liu, et al.
Future Microbiology|December 13, 2016
Evaluation of the automated Becton Dickinson MAX real-time PCR platform for detection of Pneumocystis jiroveciiJung-Yien Chien, Chia-Jung Liu, Pei-Chien Chuang, et al.
Journal of Fungi (Basel, Switzerland)|July 2, 2021
Establishing Aspergillus-Specific IgG Cut-Off Level for Chronic Pulmonary Aspergillosis Diagnosis: Multicenter Prospective Cohort StudyMeng-Rui Lee, Hung-Ling Huang, Li-Ta Keng, et al.
Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi|September 25, 2018
Impact of prior pulmonary tuberculosis in treatment outcomes of HCAP and CAP patients in intensive care unitsFan-Min Lin, Jia-Yih Feng, Wen-Feng Fang, et al.
Infectious Diseases and Therapy|February 11, 2023
Incidence of and Risk Factors for Acute Kidney Injury During Antituberculosis Treatment: A Prospective Cohort Study and Literature ReviewChia-Hao Chang, Lih-Yu Chang, Jen-Chung Ko, et al.
BMC Cancer|March 14, 2023
Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitorsChun-Ta Huang, Chih-An Lin, Te-Jen Su, et al.
Pageof 48